{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:01:28Z","timestamp":1789848088515,"version":"4.0.1"},"reference-count":29,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective.<\/jats:bold>\n                    Adrenal insufficiency is predominantly managed by glucocorticoids, from which hydrocortisone is most frequently prescribed. However, limited data are available on prescription patterns among Indian healthcare professionals (HCPs). This study assessed the prescription practices of hydrocortisone among Indian HCPs and evaluated their awareness of tapering protocols and necessity for modified-release formulations of hydrocortisone.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.<\/jats:bold>\n                    This online questionnaire-based survey involved 300 HCPs across India who prescribe oral hydrocortisone for various endocrinological and non-endocrinological indications. Google Forms were used and survey was carried out over a period of two months. Only fully accomplished responses were included in the analysis and the response rate was calculated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    The survey response rate was 84.27%. Among HCPs, 94.7% prescribed oral hydrocortisone with 47.5% using it often and 28.9% very often. Prescription frequency varied from 29.9% (prescribed once weekly) to 25.7% (two or more times weekly). Awareness of approved indications was high (96.8%). Tapering protocols were widely practiced (95.4%) often or very often by 82.7% HCPs. Hydrocortisone was mainly prescribed for primary adrenal insufficiency (77.5%), secondary adrenal insufficiency (63.0%), and congenital adrenal hyperplasia (55.6%). Frequent adverse events included hyperglycemia (43.3%) and weight gain (43.0%). Most HCPs (89.8%) felt need for sustained-release hydrocortisone, particularly for primary adrenal insufficiency (81.7%). Alternatives of hydrocortisone mainly included prednisolone (65.8%), prednisone (37.3%), and dexamethasone (21.8%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    Indian HCPs frequently prescribe oral hydrocortisone and are well-versed in tapering protocols. However, frequent adverse events and unmet needs emphasize strong demand for modified-release formulations, particularly for management of adrenal insufficiency.\n                  <\/jats:p>","DOI":"10.2478\/enr-2026-0022","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:09:14Z","timestamp":1789844954000},"page":"213-220","source":"Crossref","is-referenced-by-count":0,"title":["Prescription pattern of oral hydrocortisone by Indian healthcare professionals: An online questionnaire-based survey"],"prefix":"10.2478","volume":"60","author":[{"given":"Rama","family":"Valia","sequence":"first","affiliation":[{"name":"1 Department of Endocrinology , Postgraduate Institute of Medical Education and Research (PGIMER) , Chandigarh , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish Kumar","family":"Jangir","sequence":"additional","affiliation":[{"name":"2 Department of Endocrinology , Indus Jaipur Hospital , Jaipur , Rajasthan , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danendra","family":"Sahu","sequence":"additional","affiliation":[{"name":"3 Department of Endocrinology , Fortis Hospital , New Delhi , Delhi , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayakrishnan C","family":"Menon","sequence":"additional","affiliation":[{"name":"4 Department of Endocrinology , Jubilee Mission Medical College & Research Institute , Kerala , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Varghese","sequence":"additional","affiliation":[{"name":"5 Department of Endocrinology , Holy Family Multispeciality Hospital , Mumbai , Maharashtra , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam","family":"Sundar","sequence":"additional","affiliation":[{"name":"6 Grapes Clinic , Rajarajeshwari Nagar , Bangalore, Karnataka , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Yadav","sequence":"additional","affiliation":[{"name":"7 Medical Affairs , Samarth Life Sciences Pvt Ltd. , Bangur Nagar , Goregaon (W), Mumbai , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kamble","sequence":"additional","affiliation":[{"name":"7 Medical Affairs , Samarth Life Sciences Pvt Ltd. , Bangur Nagar , Goregaon (W), Mumbai , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"2026091919090676577_j_enr-2026-0022_ref_001","doi-asserted-by":"crossref","unstructured":"Abad-Santos F, Zapater P, Novalbos J, Gallego-Sandin S, Galvez-Mugica MA, Priego J, Garcia AG. Survey of oral hydrocortisone utilization in Madrid (Spain). Pharmacol Res 45, 15\u201320, 2002.","DOI":"10.1006\/phrs.2001.0896"},{"key":"2026091919090676577_j_enr-2026-0022_ref_002","doi-asserted-by":"crossref","unstructured":"Alam MM, Tariq M, Bondugulapati LNR, Pasha MA, Bashir J, Hassan U, Ahmad Awan T. Assessing the knowledge of sick-day rules among patients on long-term glucocorticoids and healthcare professionals in a UK district general hospital. Ibnosina J Med Biomed Sci 15, 33\u201336, 2023.","DOI":"10.1055\/s-0042-1750181"},{"key":"2026091919090676577_j_enr-2026-0022_ref_003","doi-asserted-by":"crossref","unstructured":"Alvarez de la Rosa D, Ramos-Hernandez Z, Weller-Perez J, Johnson TA, Hager GL. The impact of mineralocorticoid and glucocorticoid receptor interaction on corticosteroid transcriptional outcomes. Mol Cell Endocrinol 594, 112389, 2024.","DOI":"10.1016\/j.mce.2024.112389"},{"key":"2026091919090676577_j_enr-2026-0022_ref_004","doi-asserted-by":"crossref","unstructured":"Booker QS, Austin JD, Balasubramanian BA. Survey strategies to increase participant response rates in primary care research studies. Fam Pract 38, 699\u2013702, 2021.","DOI":"10.1093\/fampra\/cmab070"},{"key":"2026091919090676577_j_enr-2026-0022_ref_005","doi-asserted-by":"crossref","unstructured":"Bugrul F, Murat NO. Treatment and follow-up of non-stress adrenal insufficiency. J Clin Res Pediatr Endocrinol 17, 93\u2013101, 2025.","DOI":"10.4274\/jcrpe.galenos.2024.2024-6-23-S"},{"key":"2026091919090676577_j_enr-2026-0022_ref_006","doi-asserted-by":"crossref","unstructured":"Caetano CM, Malchoff CD. Daily glucocorticoid replacement dose in adrenal insufficiency: a mini review. Front Endocrinol (Lausanne) 13, 897211, 2022.","DOI":"10.3389\/fendo.2022.897211"},{"key":"2026091919090676577_j_enr-2026-0022_ref_007","doi-asserted-by":"crossref","unstructured":"Chua A, Yoeli H, Till D, Dashora U, Oyibo P, Drake WM, Cartwright M, Llahana S. Factors influencing self-management of adrenal crisis in patients with adrenal insufficiency: a qualitative study. Endocr Connect 14, e240651, 2025.","DOI":"10.1530\/EC-24-0651"},{"key":"2026091919090676577_j_enr-2026-0022_ref_008","doi-asserted-by":"crossref","unstructured":"Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids: recent developments and mechanistic insights. Mol Cell Endocrinol 335, 2\u201313, 2011.","DOI":"10.1016\/j.mce.2010.04.005"},{"key":"2026091919090676577_j_enr-2026-0022_ref_009","doi-asserted-by":"crossref","unstructured":"Ekman B, Fitts D, Marelli C, Murray RD, Quinkler M, Zelissen PM. European Adrenal Insufficiency Registry (EUAIR): a comparative observational study of glucocorticoid replacement therapy. BMC Endocr Disord 14, 40, 2014.","DOI":"10.1186\/1472-6823-14-40"},{"key":"2026091919090676577_j_enr-2026-0022_ref_010","doi-asserted-by":"crossref","unstructured":"Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D, Hasenmajer V, Sbardella E, Gianfrilli D, Pozza C, Pasqualetti P, Morrone S, Santoni A, Naro F, Colao A, Pivonello R, Lenzi A. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol 6, 173\u2013185, 2018.","DOI":"10.1016\/S2213-8587(17)30398-4"},{"key":"2026091919090676577_j_enr-2026-0022_ref_011","doi-asserted-by":"crossref","unstructured":"Khalili F, Burt MG. Practical guidance for stopping glucocorticoids. Aust Prescr 48, 116\u2013121, 2025.","DOI":"10.18773\/austprescr.2025.037"},{"key":"2026091919090676577_j_enr-2026-0022_ref_012","doi-asserted-by":"crossref","unstructured":"Llahana S, Anthony J, Sarafoglou K, Geffner ME, Ross R. Patient and caregiver experiences with hydrocortisone injections in adrenal crisis: a mixed-methods cross-sectional study. Front Endocrinol (Lausanne) 16, 1544502, 2025.","DOI":"10.3389\/fendo.2025.1544502"},{"key":"2026091919090676577_j_enr-2026-0022_ref_013","doi-asserted-by":"crossref","unstructured":"Mahlab-Guri K, Asher I, Sthoeger Z. Immediate and delayed hypersensitivity reactions to corticosteroids \u2013 prevalence, diagnosis and treatment. Swiss Med Wkly 153, 40025, 2023.","DOI":"10.57187\/smw.2023.40025"},{"key":"2026091919090676577_j_enr-2026-0022_ref_014","doi-asserted-by":"crossref","unstructured":"Mathew S, Finny P, Johnson SA, Maria M, Samuel PS, Armstrong LJ, David A. Evaluation of glucocorticoids utilization in Central Kerala using pharmacy sales overview. Indian J Endocrinol Metab 25, 516\u2013519, 2021.","DOI":"10.4103\/ijem.ijem_439_21"},{"key":"2026091919090676577_j_enr-2026-0022_ref_015","doi-asserted-by":"crossref","unstructured":"Merke DP, Mallappa A, Arlt W, Brac de la Perriere A, Linden Hirschberg A, Juul A, Newell-Price J, Perry CG, Prete A, Rees DA, Reisch N, Stikkelbroeck N, Touraine P, Maltby K, Treasure FP, Porter J, Ross RJ. Modified-release hydrocortisone in congenital adrenal hyperplasia. J Clin Endocrinol Metab 106, e2063\u2013e2077, 2021.","DOI":"10.1210\/clinem\/dgab051"},{"key":"2026091919090676577_j_enr-2026-0022_ref_016","doi-asserted-by":"crossref","unstructured":"Neumann U, Blankenstein O, Claahsen-van der Grinten HL. Treatment with hydrocortisone modified-release capsules in children and adolescents with congenital adrenal hyperplasia: an expert opinion. Endocr Connect 14, e240619, 2025.","DOI":"10.1530\/EC-24-0619"},{"key":"2026091919090676577_j_enr-2026-0022_ref_017","doi-asserted-by":"crossref","unstructured":"Oprea A, Bonnet NCG, Polle O, Lysy PA. Novel insights into glucocorticoid replacement therapy for pediatric and adult adrenal insufficiency. Ther Adv Endocrinol Metab 10, 1\u201327, 2019.","DOI":"10.1177\/2042018818821294"},{"key":"2026091919090676577_j_enr-2026-0022_ref_018","doi-asserted-by":"crossref","unstructured":"Priya G, Laway BA, Ayyagari M, Gupta M, Bhat GHK, Dutta D. The glucocorticoid taper: a primer for the clinicians. Indian J Endocrinol Metab 28, 350\u2013362, 2024.","DOI":"10.4103\/ijem.ijem_410_23"},{"key":"2026091919090676577_j_enr-2026-0022_ref_019","doi-asserted-by":"crossref","unstructured":"Rifaei SM, Etoom S, Hanandeh SA, Ali SH, Alzboon AM, Al-Jaraideh MD, Aktham S, Hamad KKM, Alharoun M, Alkhatib AJ. Public awareness of corticosteroid use and side effects: a cross-sectional study from Jordan. Mater Sociomed 37, 24\u201331, 2025.","DOI":"10.5455\/msm.2025.37.24-31"},{"key":"2026091919090676577_j_enr-2026-0022_ref_020","doi-asserted-by":"crossref","unstructured":"Ross RJM, Arlt W, de la Perriere AB, Hirschberg AL, Juul A, Merke DP, Newell-Price JDC, Prete A, Rees DA, Reisch N, Stikkelbroeck M, Touraine PA, Maltby K, Quirke J, Coope H, Porter J. Switching patients with congenital adrenal hyperplasia to modified-release hydrocortisone capsules: relative bioavailability and disease control. Clin Endocrinol (Oxf) 103, 290\u2013293, 2025.","DOI":"10.1111\/cen.15275"},{"key":"2026091919090676577_j_enr-2026-0022_ref_021","doi-asserted-by":"crossref","unstructured":"Rushworth RL, Torpy DJ. The changing epidemiology of adrenal insufficiency: iatrogenic factors predominate. J Endocr Soc 7, bvad017, 2023.","DOI":"10.1210\/jendso\/bvad017"},{"key":"2026091919090676577_j_enr-2026-0022_ref_022","doi-asserted-by":"crossref","unstructured":"Selvido DI, Bhattarai BP, Niyomtham N, Riddhabhaya A, Vongsawan K, Pairuchvej V, Wongsirichat N. Review of dexamethasone administration for management of complications in postoperative third molar surgery. J Korean Assoc Oral Maxillofac Surg. 47, 341\u2013350, 2021.","DOI":"10.5125\/jkaoms.2021.47.5.341"},{"key":"2026091919090676577_j_enr-2026-0022_ref_023","unstructured":"Seth A, Aggarwal A. Monitoring adverse reactions to steroid therapy in children. Indian Pediatr 41, 349\u2013357, 2004."},{"key":"2026091919090676577_j_enr-2026-0022_ref_024","doi-asserted-by":"crossref","unstructured":"Sridhar S, Balachandran K, Nazirudeen R, Natarajan V, Sangumani J. Clinical profile of Addison\u2019s disease in a tertiary care institute, Southern India \u2013 the changing landscape. Indian J Endocrinol Metab 26, 50\u201354, 2022.","DOI":"10.4103\/ijem.ijem_164_21"},{"key":"2026091919090676577_j_enr-2026-0022_ref_025","doi-asserted-by":"crossref","unstructured":"Steintorsdottir SD, Oksnes M, Jorgensen AP, Husebye ES. Extended-release hydrocortisone formulations - Is there a clinically meaningful benefit? J Clin Endocrinol Metab 110, e566\u2013e573, 2025.","DOI":"10.1210\/clinem\/dgae822"},{"key":"2026091919090676577_j_enr-2026-0022_ref_026","doi-asserted-by":"crossref","unstructured":"Tavares LCP, Caetano LVN, Ianhez M. Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know. An Bras Dermatol 99, 259\u2013268, 2024.","DOI":"10.1016\/j.abd.2023.05.005"},{"key":"2026091919090676577_j_enr-2026-0022_ref_027","doi-asserted-by":"crossref","unstructured":"Wallace BI, Cohen-Mekelburg S, Van T, Lipson R, Kenney B, Tatchin C, Baker J, Saini SD, Waljee AK. A national cross-sectional study of the role of clinician specialty and facility complexity on glucocorticoid prescribing in Veterans. Commun Med (Lond) 5, 184, 2025.","DOI":"10.1038\/s43856-025-00869-9"},{"key":"2026091919090676577_j_enr-2026-0022_ref_028","doi-asserted-by":"crossref","unstructured":"Whitaker M, Debono M, Huatan H, Merke D, Arlt W, Ross RJ. An oral multiparticulate, modified-release, hydro-cortisone replacement therapy that provides physiological cortisol exposure. Clin Endocrinol (Oxf) 80, 554\u2013561, 2014.","DOI":"10.1111\/cen.12316"},{"key":"2026091919090676577_j_enr-2026-0022_ref_029","doi-asserted-by":"crossref","unstructured":"Wondmkun YT, Ayele AG. Assessment of prescription pattern of systemic steroidal drugs in the outpatient department of Menelik II Referral Hospital, Addis Ababa, Ethiopia, 2019. Patient Prefer Adherence 15, 9\u201314, 2021.","DOI":"10.2147\/PPA.S285064"}],"container-title":["Endocrine Regulations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/enr-2026-0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:09:23Z","timestamp":1789844963000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/enr-2026-0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,9,19]]},"published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.2478\/enr-2026-0022"],"URL":"https:\/\/doi.org\/10.2478\/enr-2026-0022","relation":{},"ISSN":["1336-0329"],"issn-type":[{"value":"1336-0329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]}}}